37239059 - scientists examined dna gel that is used in genetics, medicine, biology, pharma research and forensics.

New DNA genetic kit for Clinical Endo-Cannabinoid Deficiency Tests for Cannabis Side Effects

A joint collaboration has resulted in world’s first genetic kit measuring for Clinical Endo-Cannabinoid Deficiency (CECD). CECD was originally theorized by Dr. Ethan Russo (1) in his 2004 article and is believed to be responsible for migraine, fibromyalgia, inflammatory bowel disease and other related conditions that effectively and collectively impact over 20% of the U.S. population. Physicians now will be capable of obtaining genetic insight leading to preventative care, symptom management and best of all – individual systemic improvement based on genomics technologies.

There are currently an estimated 19,000 – 20,000 individual human protein coding-genes in an individual’s sequence – that’s down from what was originally predicted to be well over 100,000 and could continue to change as genomic technologies advance. Cannalogix’s collaboration with the world’s leading genomics expert on the ECS, Dr. Rahul Kushwah has revealed the necessary pathways and gene expressions to identify CECD.  Given that ability, the CECD genetic kit will provide both the medical professional and the patient with the tools necessary to start down a corrective path to optimal wellness.

The package, known as CECD.SOLUTIONS will be available early Spring 2018 over the internet at http://CECD.SOLUTIONS/ at the consumer price of $1,500.00, and could save patients thousands of dollars over a lifetime and countless hours of trial and error – not to mention eliminating the unnecessary anxiety, undesired psycho-activity and waste of time, energy and cost. Cannalogix plans to distribute the kits to managed care and independent medical professionals, hospitals, and clinics worldwide through global distribution by late 2018.

Anantlife’s and Cannalogix’s collaborative efforts will revolutionize the healthcare system and further normalize the use of medical cannabis by educating and empowering medical professionals in correcting the deficiencies that plague our society. These advancements will lead to increased levels of personal individualized care while decreasing the burdens on an already overwhelmed and overburdened healthcare system by subsequently lowering the cost of clinical care, health insurance, hospitalization and prescription drug coverage for millions of already under-funded and disadvantaged families in America. This is the first development in a series of cutting-edge genetic kits and commercialized products that are being released by the incubator – meant to revolutionize healthcare and lower the overall burden of medical expenses on the patient, the healthcare system and the American tax-payers.

Cannalogix’s Chief Research Officer – J.B. Creel states – “Today we introduce you to the future of cognitive and wellness optimization. Anantlife and Cannalogix are pleased to announce our joint-collaboration has resulted in a genetic kit that can identify an endocannabinoid deficiency through DNA analysis. Where can we go from this? Only time and our continued efforts will tell. Anantlife’s initial “worlds-first” Cannabis Genetic Kit looking into one’s predisposition to side-effects and addiction was revolutionary for patients. The further co-development of the CECD Genetic Kit puts medical science one step closer to winning the war on Endo-Cannabinoid Deficiency – potentially allowing the correction of the root causes of fibromyalgia, migraines, inflammatory bowel disease and many more illnesses. Considering the tendency of the foundation to facilitate the change we wish to see in the world, we are excited to have Anantlife on board and look forward to what future co-developments will manifest from our joint collaboration. I would also like to thank Dr. Rahul Kushwah and Anantlife Canada for joining the SRCF- Cannalogix Brain-Trust and helping the CFRI R&D Incubator and its co-developers foster a happy, healthy humanity for all.”

Patients on limited income can still access the package through the SRCF, Cannalogix, and other non-profit clinics via scholarships and or low-to-no interest in-house financing (credit, not a factor – backed by project co-developers) with low monthly payments of only $50 until the package is paid off – please see http://CECD.SOLUTIONS/in-house-financing/ for full details. In an effort to increase quality of care, the foundation is integrating all of Anantlife’s genetic kits into the intake process, as well as all on-going in-patient and outpatient care. Proceeds from the CECD.SOLUTIONS package will go to SRCF and CFRI projects that either serve Veteran, Disabled, Indigent or Pediatric patients and or further research to continue our collective goal of fostering a happier, healthier humanity – naturally. The CECD.SOLUTIONS package, in addition to the entire line of Anantlife’s genetic kits, will be distributed by the Cannalogix International Research and Care (CIRC) Network providers.

The CECD.SOLUTIONS package includes; 1.) CECD genetic decoding, by Anantlife Canada; 2.) a companion outline of beneficial strains, phyto-cannabinoids and terpenoids, by Cannalogix – IP Holdings; 3.) an app to track progress with a built in guide of all available resources for medical, nutrigenetic, epigenetic, and immunogenetic experts and specialists that work with the specific condition(s) – including those within the Cannalogix International Research and Care (CIRC) Network, and clinics that work with low income and disadvantaged in complimentary care, by Xendance Medical Technologies; 4.) 1 full year membership in the SRCF and email support with access to a care coordinator in case the patient might need a referral to a specialist, by SRCFCANNALOGIX, and 5.) access to low-to-no interest financing, by Bluebird & Blacksheep so the test is accessible to all. As an extension of the SRCF-Cannalogix family of organizations – following its commitment to inclusion and diversity without barriers, the CECD.SOLUTIONS package will be made affordable for all patients, regardless of income, location, or circumstance.

Skip to toolbar